Semaglutide Research Updates: Clinical Evidence and New Findings

Semaglutide research now extends beyond blood glucose and body-weight measurements. Large clinical trials have examined cardiovascular events, chronic kidney disease, and outcomes in specific patient populations, while newer analyses continue to explore where the evidence is strongest and where uncertainty remains.

For researchers and readers tracking scientific developments, the important question is not simply whether a study reports a positive result. It is what the trial measured, which participants were included, and whether the findings can be applied beyond that specific population. This review covers major semaglutide research milestones, notable findings, and the limitations that should guide interpretation.

1. How Semaglutide Research Has Evolved

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Its clinical development initially focused heavily on glucose regulation in type 2 diabetes. Research subsequently expanded into obesity, cardiovascular outcomes, kidney disease, and other areas of metabolic health.

Several milestones illustrate this progression:

• Diabetes research: Clinical trials established semaglutide’s effects on glycemic control and related metabolic outcomes in defined populations.
• Obesity research: The STEP trial programme examined body-weight changes and other outcomes in people with overweight or obesity.
• Cardiovascular research: The SELECT trial investigated major cardiovascular events in adults with established cardiovascular disease and overweight or obesity who did not have diabetes.
• Kidney research: The FLOW trial evaluated kidney and cardiovascular outcomes in participants with type 2 diabetes and chronic kidney disease.
• Longer-term and subgroup analyses: Researchers have continued to examine whether findings remain consistent across different baseline risk profiles and disease-severity groups.

These areas should not be treated as interchangeable. A trial demonstrating an effect on body weight does not automatically establish an effect on kidney failure or cardiovascular events. Each outcome requires suitable evidence.

2. Obesity Research: What the STEP Trials Established

The STEP clinical-trial programme helped establish a substantial evidence base for semaglutide in obesity research.

One of its most widely cited studies, STEP 1, was published in The New England Journal of Medicine in 2021. It enrolled 1,961 adults with overweight or obesity who did not have diabetes. Participants received semaglutide or placebo alongside lifestyle intervention for 68 weeks.

At the end of the trial, mean body-weight change was approximately −14.9% in the semaglutide group and −2.4% in the placebo group.

This result demonstrated a meaningful difference between the groups under the study conditions. However, several details matter when interpreting it.

First, the reported figures are group averages. They do not mean that every participant experienced the same change. Second, the trial enrolled a defined population, so the results should not automatically be generalized to all adults or every clinical setting. Third, adverse events and treatment discontinuations are part of the evidence and should be considered alongside efficacy.

The wider STEP programme investigated different populations and research questions, including participants with type 2 diabetes. Researchers should therefore identify the exact trial rather than referring to all semaglutide obesity studies as if they were identical.

3. SELECT: Cardiovascular Outcomes Beyond Diabetes

One of the most significant developments in semaglutide research was the SELECT trial, published in 2023.

SELECT enrolled 17,604 adults aged 45 years or older who had established cardiovascular disease and overweight or obesity, but no history of diabetes. Participants were randomized to receive semaglutide 2.4 mg or placebo, with an average follow-up of approximately 40 months.

The primary endpoint was a composite of three major cardiovascular events:

• Death from cardiovascular causes
• Nonfatal myocardial infarction
• Nonfatal stroke

A primary endpoint event occurred in 6.5% of participants assigned to semaglutide and 8.0% assigned to placebo. The hazard ratio was 0.80, with a 95% confidence interval of 0.72 to 0.90.

This corresponds to a 20% relative reduction in the risk of the composite endpoint during the trial. It does not mean that every cardiovascular event was reduced by 20%, nor does it mean that every participant experienced a benefit.

Why the SELECT findings matter

SELECT addressed an important research question: whether semaglutide could reduce major cardiovascular events in a high-risk population with overweight or obesity, even when participants did not have diabetes.

Its findings expanded the evidence base beyond studies focused primarily on glucose regulation or body-weight change.

However, the population is crucial to interpretation. Participants already had cardiovascular disease, and the findings should not automatically be applied to people with no established cardiovascular disease or to populations that were not represented in the trial.

The study also reported more adverse events leading to permanent discontinuation of the trial product in the semaglutide group than in the placebo group. A balanced account should consider both the cardiovascular endpoint and treatment tolerability.

4. FLOW: Semaglutide and Chronic Kidney Disease

The FLOW trial added another important area of evidence. Published in The New England Journal of Medicine in 2024, it investigated kidney and cardiovascular outcomes in people with type 2 diabetes and chronic kidney disease.

Researchers randomized 3,533 participants to receive semaglutide 1.0 mg or placebo. The primary outcome was a composite that included major kidney disease events and death from kidney-related or cardiovascular causes.

The trial reported a 24% lower relative risk of the primary composite outcome in the semaglutide group than in the placebo group, with a hazard ratio of 0.76 and a 95% confidence interval of 0.66 to 0.88.

The result supports the role of semaglutide research in understanding outcomes beyond blood glucose and body weight.

How to interpret a composite kidney endpoint

A composite endpoint combines multiple outcomes into one measure. This can help researchers evaluate clinically important events within a single analysis, particularly when individual events are less common.

However, a composite result does not mean that every component changed by the same amount. Readers should examine the study’s definitions and results for the individual components when available.

FLOW also enrolled a specific population with type 2 diabetes and chronic kidney disease. It should not be interpreted as direct proof of identical kidney benefits in people without diabetes or in every stage of kidney disease.

5. Newer Research: Looking Beyond the Main Trial Result

Clinical research continues after a major trial publication. Follow-up analyses can help determine whether findings are consistent across groups with different baseline characteristics.

For example, a 2026 analysis of the FLOW trial examined kidney and survival outcomes across categories of chronic kidney disease severity. It reported generally consistent effects on the primary kidney outcome across the studied estimated glomerular filtration rate and urine albumin-to-creatinine ratio subgroups.

This type of analysis can strengthen understanding of the original findings, but subgroup results require careful interpretation.

What subgroup analyses can tell researchers

Subgroup analyses investigate whether the estimated treatment effect differs according to a characteristic such as baseline kidney function or disease severity.

Researchers should ask:

• Were the subgroup analyses prespecified?
• Were there enough participants and events to estimate effects precisely?
• Were interaction tests used to assess differences between groups?
• Were many subgroup comparisons conducted?
• Are the findings consistent with the overall trial result?

A result that appears statistically significant in one subgroup but not another does not necessarily prove that the treatment effect differs between those groups. The difference itself needs appropriate statistical evaluation.

Why follow-up studies matter

Secondary analyses can identify patterns that warrant additional investigation and help researchers understand the boundaries of existing evidence.

They do not replace the original randomized trial, and they cannot automatically establish a new indication. Findings from a defined trial population should remain tied to the population, endpoints, and methods that produced them.

6. Oral and Injectable Formulations: Avoid Mixing the Evidence

Semaglutide is available in different formulations, depending on the product and jurisdiction. Research findings from one formulation should not automatically be transferred to another.

Formulations may differ in administration, exposure, studied populations, and approved indications. A study evaluating an oral formulation for one endpoint may not provide the same evidence as a trial evaluating an injectable formulation for another endpoint.

When reviewing a publication, verify:

1. Which formulation was studied.
2. The specific product and research indication.
3. The study population and comparator.
4. The endpoint and follow-up period.
5. Whether the result supports a regulatory claim or only a research hypothesis.

This distinction is particularly important when media reports summarize results from several semaglutide programmes under a single general label.

7. Safety Findings Must Be Interpreted Alongside Efficacy

No review of semaglutide research is complete without examining adverse events and treatment discontinuation.

Gastrointestinal events, including nausea, vomiting, diarrhea, and constipation, have been reported in clinical trials. Their frequency and severity vary across studies and treatment settings.

Researchers should distinguish between:

• Any adverse event: An unfavorable medical occurrence during a study, whether or not it was caused by the investigational treatment.
• Serious adverse event: An event meeting regulatory seriousness criteria, such as hospitalization or a life-threatening outcome.
• Treatment-related adverse event: An event assessed as potentially related to the treatment.
• Discontinuation due to an adverse event: A participant stopping the study treatment because of an event.

These categories are not equivalent. An adverse event occurring during a trial does not, by itself, establish causation.

Trial duration also affects what can be learned. Large studies with extended follow-up provide more information about outcomes than short studies, but no individual trial can resolve every question about rare events or lifelong exposure.

For scientific reporting, the strongest approach is to discuss efficacy and safety together and to use the original study’s definitions.

8. Regulatory Status and Research Evidence Are Different

Clinical evidence and regulatory authorization are related, but they are not the same.

A positive trial can support a regulatory submission, but authorization depends on review of the total evidence, including efficacy, safety, manufacturing quality, and the proposed indication. Approval may also differ by product, formulation, and country.

Semaglutide products have approved indications in certain jurisdictions. However, readers should check the current official product information before making claims about a specific use, formulation, or market.

Researchers should also distinguish regulated pharmaceutical products from materials sold online as research compounds. A seller’s certificate of analysis or product description does not establish regulatory approval, clinical quality, or suitability for human use.

9. A Practical Framework for Evaluating Semaglutide Studies

Use this checklist when reviewing a new research paper or news announcement.

Identify the research question. Is the study evaluating body weight, glycemic control, cardiovascular events, kidney outcomes, or another endpoint?

Check the population. Were participants living with diabetes, obesity, established cardiovascular disease, chronic kidney disease, or a combination of conditions?

Confirm the comparator. Was semaglutide compared with placebo, standard care, or another active treatment?

Review the primary endpoint. Was the main endpoint met, and was it specified before the results were analyzed?

Examine the size of the effect. Look at absolute event rates, relative effects, confidence intervals, and the time period over which outcomes were measured.

Read the safety tables. Check adverse events, serious events, and treatment discontinuations.

Assess the evidence source. Distinguish a peer-reviewed publication from a conference abstract, registry update, sponsor announcement, or secondary analysis.

Read the limitations. Consider participant selection, missing data, follow-up duration, and whether the findings apply beyond the studied population.

This process makes it easier to separate a genuine research advance from a claim that goes beyond the available evidence.

Frequently Asked Questions

What are the most important semaglutide research findings?

Major findings include evidence from obesity trials, the SELECT cardiovascular outcomes trial, and the FLOW chronic kidney disease trial. Each addresses a different research question and applies to a defined population.

Did semaglutide reduce cardiovascular events in people without diabetes?

In SELECT, semaglutide reduced the incidence of the primary composite cardiovascular endpoint compared with placebo among participants with established cardiovascular disease and overweight or obesity who did not have diabetes. The finding should not be generalized to every population.

What did the FLOW trial investigate?

FLOW investigated kidney and cardiovascular outcomes in people with type 2 diabetes and chronic kidney disease. Its primary composite outcome occurred less frequently in the semaglutide group than in the placebo group.

Do all semaglutide formulations have the same evidence base?

No. Evidence depends on the specific formulation, product, studied population, endpoint, and indication. Results from one formulation should not automatically be transferred to another.

Why do researchers publish follow-up analyses?

Follow-up analyses can examine consistency across subgroups, explore additional outcomes, and identify questions for future research. They should be interpreted alongside the original trial and its statistical plan.

Conclusion

Semaglutide research has progressed from glucose-focused studies to a wider body of evidence examining obesity, cardiovascular outcomes, and chronic kidney disease. SELECT and FLOW are particularly important because they investigated clinically meaningful outcomes beyond changes in body weight or blood glucose.

The most reliable interpretation comes from matching every finding to its original study population, endpoint, and follow-up period. As newer analyses appear, readers should distinguish primary trial results from subgroup findings and avoid applying results beyond the populations actually studied.

Research disclaimer: This article is for scientific and educational purposes only. It does not provide medical advice or recommend the use, purchase, or administration of any compound. Clinical findings should be evaluated using original peer-reviewed publications and current official regulatory information.